CD117 - Revision history

John at 19:46, 4 July 2023

2023-07-04T19:46:21Z

← Older revision		Revision as of 21:46, 4 July 2023
Line 60:		Line 60:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-		\|-
	!colspan="8"\|'''Expression: mature B cell neoplasms'''		!colspan="8"\|'''Expression in mature B cell neoplasms'''
	\|-		\|- <span style="font-size:70%">
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%

John at 11:16, 3 July 2023

2023-07-03T11:16:02Z

← Older revision		Revision as of 13:16, 3 July 2023
Line 43:		Line 43:
	!AML!!CMML !!B ALL !!BL \|\|T ALL !!ETP ALL !!MPAL \|\|Hgn</span>		!AML!!CMML !!B ALL !!BL \|\|T ALL !!ETP ALL !!MPAL \|\|Hgn</span>
	\|-<span style="font-size:70%">		\|-<span style="font-size:70%">
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 12.5%; background: #006699; color:white"\|40-80%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 12.5%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background:#66e0ff; color:black"\|5-20%		\|style="width: 12.5%; background:#66e0ff; color:black"\|5-20%
	\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background:#66e0ff; color:black"\|5-20%		\|style="width: 12.5%; background:#66e0ff; color:black"\|5-20%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 12.5%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 12.5%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%		\|style="width: 12.5%; background: #00b8e6; color:black"\|20-40%
	\|-		\|-
	\|}		\|}

John at 11:14, 3 July 2023

2023-07-03T11:14:28Z

← Older revision		Revision as of 13:14, 3 July 2023
Line 44:		Line 44:
	\|-<span style="font-size:70%">		\|-<span style="font-size:70%">
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
			\|style="width: 14.25%; background: #00b8e6; color:black"\|20-40%
	\|style="width: 14.25%; background:#66e0ff; color:black"\|5-20%		\|style="width: 14.25%; background:#66e0ff; color:black"\|5-20%
	\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%		\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%

John at 11:12, 3 July 2023

2023-07-03T11:12:34Z

← Older revision		Revision as of 13:12, 3 July 2023
Line 37:		Line 37:


	{\| class=wikitable style="text-align: center; font-size:80%; width: ~~87.5~~%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-
	~~!colspan="7"\|<span style="font-size:100%">'''Expression: primitive cell types''' ''Click (i) on table for additional information'' </span></font>~~
	\|-
	~~! AML !! B ALL !! Burkitt \|\| T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)\|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)\|i]]) \|\| H.gones ('''[[Haematogones\|i]]''')~~
	\|-		\|-
			!colspan="8"\|'''Expression in primitive cell types'''</font>
			\|- <span style="font-size:70%">
			!AML!!CMML !!B ALL !!BL \|\|T ALL !!ETP ALL !!MPAL \|\|Hgn</span>
			\|-<span style="font-size:70%">
	\|style="width: 14.25%; background: #006699; color:white"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
	\|style="width: 14.25%; background:#66e0ff; color:black"\|5-20%		\|style="width: 14.25%; background:#66e0ff; color:black"\|5-20%

John: Created page with "
:'''Summary''' :CD117 is a widely expressed molecule that in haematology is used most often as a marker of primitive myeloid cells where it contributes to a diagnosis of AML. However expression is absent in around 20-30% of typical AML and there is recognised aberrant expression by up to 30% of ALL cases (more frequently in T lineage). CD11..."

2023-06-12T10:42:03Z

Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :'''Summary''' :CD117 is a widely expressed molecule that in haematology is used most often as a marker of primitive myeloid cells where it contributes to a diagnosis of AML. However expression is absent in around 20-30% of typical AML and there is recognised aberrant expression by up to 30% of ALL cases (more frequently in T lineage). CD11..."

New page

<div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;">

:'''Summary'''

:CD117 is a widely expressed molecule that in haematology is used most often as a marker of primitive myeloid cells where it contributes to a diagnosis of AML. However expression is absent in around 20-30% of typical AML and there is recognised aberrant expression by up to 30% of ALL cases (more frequently in T lineage). CD117 is also expressed by mast cells, and weakly on some plasma cells

</div>

'''Normal expression and function'''

CD117 was originally described in 1987 as c-kit (the cellular homolog of the feline sarcoma viral oncogene v-kit). Stem cell factor (SCF) binds to CD117 initiating signals that variously control apoptosis, differentiation, proliferation, chemotaxis or cellular adhesion. In myeloid cells, CD117 is expressed by early haematopoietic progenitor cells then expression is lost as the cells mature.

'''Diagnostic role'''

*In acute myeloid leukaemia expression of CD117 is seen in 70-80% of cases including less differentiated forms, it may be expression by any subtype, but is less likely in cases with monocytic, erythroid, or megakaryocytic maturation
*Aberrant expression in acute lymphoid leukaemias is reported - more frequently in T-lineage ALL (particularly more primitive types). Expression in B-lineage ALL is less frequent.
*Expression by mature B cell or mature T cell types is rare, although CD117 expression is described on some CD8 positive mature T cell neoplasms. *Around 30 of myeloma cases express CD117, but often expression is weak which limits its value in this disorder
*CD117 can be used to identify mast cells, but does not distinguish normal from neoplastic cells.

'''Other useful information'''

Outside of the haematopoietic system CD117 has a wide expression that includes germ cells, cajal cells of the gastrointestinal tract and epithelial cells in skin and breast. Gain-of-function mutations are seen in tumours affecting mast cells, myeloid cells, systemic mastocytosis, acute myeloid leukemia or cajal cells gastrointestinal stromal tumors - GOST tumours.

----

'''''SUMMARY TABLES'''''

{| class=wikitable style="text-align: center; font-size:80%; width: 87.5%; height 20px;"
|-
!colspan="7"|'''Expression: primitive cell types''' ''Click (i) on table for additional information'' 
|-
! AML !! B ALL !! Burkitt || T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)|i]]) || H.gones ('''[[Haematogones|i]]''')
|-
|style="width: 14.25%; background: #006699; color:white"|40-80%
|style="width: 14.25%; background:#66e0ff; color:black"|5-20%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background:#66e0ff; color:black"|5-20%
|style="width: 14.25%; background: #00b8e6; color:black"|20-40%
|style="width: 14.25%; background: #00b8e6; color:black"|20-40%
|style="width: 14.25%; background: #00b8e6; color:black"|20-40%
|-
|}

'''Notes:''' The main application is in AML. Aberrant expression is seen in ALL particularly in T-lineage, although it may be less likely in Burkitt lymphoma. CD117 expression can indicate MPAL or ETP-ALL if other markers are consistent.

{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|'''Expression: mature B cell neoplasms'''
|-
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
|-
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: #00b8e6; color:black"|20-40%
|-
|}

'''Notes:''' expression is uncommon in mature B-lymphoproliferative disorders, but may occur in plasma cells

{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"
|-
!colspan="7"|'''Expression: mature T cell neoplasms'''
|-
! ATLL !! CTCL Sezary !! T-PLL !! T-LGL !! NK-LGL
|-
|style= "width: 20%; background: #FFE4E1; color:black"|limited
|style="width: 20%; background: #FFE4E1; color:black"|limited
|style="width: 20%; background: #FFE4E1; color:black"|limited
|style= "width: 20%; background: #FFE4E1; color:black"|limited
|style="width: 20%; background: #FFE4E1; color:black"|limited
|-
|}

'''Notes:''' limited reports are consistent with expression being uncommon in T-lymphoproliferative disorders, but may occur in some cases of T-PLL

----